/

Società

Mo

Non verificato

Modalis Therapeutics Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteVetrine/Shopping

4 comunicati stampa

Guarda tutti i comunicati

12/05/2025

Eventi

Appalti e gare

Scienza

Giovani

Biotecnologia

Medicina - Varie

Farmaceutica

Vetrine/Shopping

Salute

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.

Fonte

Modalis Therapeutics Corporation

Emittente

1.00

0

06/01/2025

Multimedialità

Mercato del lavoro

Industria

Biotecnologia

Salute

Farmaceutica

JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy

Fonte

Modalis Therapeutics Corporation

Emittente

1.00

0

25/10/2024

Industria

Scienza

Biotecnologia

Farmaceutica

Salute

Igiene alimentare

Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).

Fonte

Modalis Therapeutics Corporation

Emittente

1.00

0

30/09/2024

Industria

Salute

Igiene alimentare

Vetrine/Shopping

Biotecnologia

Infanzia

Farmaceutica

Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)

Fonte

Modalis Therapeutics Corporation

Emittente

1.00

0

Seguaci

0

Compatibilità

0